



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Richard A. Slayden,
✉ richard.slayden@colostate.edu

†These authors have contributed equally to
this work

RECEIVED 27 October 2025
ACCEPTED 28 October 2025
PUBLISHED 18 November 2025

CITATION

Cummings JE, Woolhiser LK, Guglielmi V,
Wernsman M, Romano A, Pauly S, Belisle JT,
Walter ND, Robertson GT and Slayden RA (2025)
Correction: Evaluating the efficacy of HRZE-
based regimens in a high-burden murine
model: a back-translational assessment of
rifamycins and moxifloxacin substitutions in
tuberculosis treatment.
Front. Pharmacol. 16:1733648.
doi: 10.3389/fphar.2025.1733648

COPYRIGHT

© 2025 Cummings, Woolhiser, Guglielmi,
Wernsman, Romano, Pauly, Belisle, Walter,
Robertson and Slayden. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](#).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Correction: Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment

Jason E. Cummings^{1†}, Lisa K. Woolhiser^{1†}, Vincent Guglielmi¹,
Machenzie Wernsman¹, Ashley Romano¹, Samantha Pauly^{2,3},
John T. Belisle¹, Nicholas D. Walter^{2,3,4}, Gregory T. Robertson^{1,2}
and Richard A. Slayden^{1*}

¹Mycobacteria Research Laboratories, Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States, ²Consortium for Applied Microbial Metrics, Aurora, CO, United States, ³Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States, ⁴Rocky Mountain Regional VA Medical Center, Aurora, CO, United States

KEYWORDS

high-burden aerosol BALB/c model, high burden, tuberculosis, mycobacteria, drug discovery


A Correction on

Evaluating the efficacy of HRZE-based regimens in a high-burden murine model: a back-translational assessment of rifamycins and moxifloxacin substitutions in tuberculosis treatment

by Cummings JE, Woolhiser LK, Guglielmi V, Wernsman M, Romano A, Pauly S, Belisle JT, Walter ND, Robertson GT and Slayden RA (2025). *Front. Pharmacol.* 16:1667592. doi: 10.3389/fphar.2025.1667592

There was a mistake in [Figure 1](#) as published. **Figure S1** was published in place of the true [Figure 1](#). The corrected [Figure 1](#) appears below.

Supplemental material **Figure S1** was omitted. The file has now been published.
The original article has been updated.



intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Generative AI statement

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial